Ariad shoots up 43% on deal report
August 28, 2015 at 14:31 PM EDT
Drugmaker Baxalta is working to buy a U.S.-based hematology and oncology specialist valued at about $2 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.